Roche has become a global leader in a number of areas:
- No. 1 worldwide in diagnostics
- No. 1 worldwide in oncology
- Leader in transplantation and virology
- No. 2 worldwide in biotechnology
Roche has traditionally invested 15 percent of its annual gross sales in research and development, the highest percentage among its peers. This tradition of focusing on scientific research not only enables Roche to develop a variety of groundbreaking new drugs, obtaining considerable economic benefits, in addition, the social benefits of promoting human health is also extremely prominent, Roche scientists more so three times won the Nobel Prize. Currently, Roche has 10 R&D centers around the world***, located in Basel, Switzerland, Nutley and Palo Alto, USA. Among them, Roche Basel's Central Nervous System and Cardiovascular Disease Research Center and the Genetic Research Center in the U.S. enjoy high reputation in the international pharmaceutical industry. 2004 January, Roche announced the establishment of the fifth R&D center of the Pharmaceutical Division in Shanghai, China. This will be the first time that Roche has set up an R&D facility in a developing country.
Roche's Pharmaceuticals Division has a long history of producing drugs for the treatment of central nervous system diseases, infectious diseases, inflammation, cardiovascular diseases, oncology, viral infections, dermatological diseases, obesity and other types of diseases. In order to increase the variety of drugs and develop innovation, Roche in recent years has successfully acquired a number of large international pharmaceutical companies to strengthen its own strength. These include: the acquisition of the most advanced bioengineering company in the United States, the majority of the shares of the genetic technology company, in order to strengthen Roche in genetic engineering - the most advanced field of the pharmaceutical industry in the leading position; the acquisition of Nicholas company's over-the-counter drug division and Fersens, so that Roche has become the European over-the-counter market share of the largest company; 1994, Roche has become the largest over-the-counter market share; in order to increase the range of drugs to develop new innovations. The acquisition of Syntex Pharmaceuticals in 1994 doubled Roche's strength in anti-infective and organ transplantation drugs. 2001 saw the announcement of a joint venture between Roche and Chugai Pharmaceuticals of Japan to form a leading research-oriented Japanese pharmaceutical company, a full-featured Japan-based multinational, ranked as the world's 2nd largest pharmaceutical market - 5th in the Japanese market. -- 5th in the Japanese market.
Roche's Medical Diagnostics division has grown at a phenomenal pace since its establishment in 1968. The reagents produced by this division are widely used in medical immunology tests, such as pregnancy tests, hepatitis tests, HIV tests, etc. In 1994, Roche's biomedical laboratories were merged with the U.S. National Health Laboratories to form the U.S. Laboratories Organization (USLO), the world's largest organization of clinical medical laboratories, of which Roche owns a 49.9% stake. In medical diagnostics, the Roche Molecular Laboratory is another Roche research organization with outstanding achievements. The laboratory is currently working on the research of polymerase chain reaction (PCR) technology, which is capable of duplicating the same gene or DNA fragment, and can be widely used in basic research, diagnosis of AIDS, tuberculosis, leukemia, and environmental testing. in early 1998, Roche completely completed the merger of Bowling Green Mann, absorbing the company's strengths in the product, and became the leader in the field of medical diagnostics. in 2003, Roche became the leader in the field of medical diagnostic. In 2003, Roche successfully acquired the world's second largest insulin pump manufacturer, Swiss Disetronic, making Roche Diagnostics, a world leader in diabetes monitoring, the leading supplier of integrated diabetes control systems.
We can't talk about Roche without mentioning Tamiflu. The scientific name of Tamiflu is "Oseltamivir", English Oseltamivir, is a patented product of Roche, in recent years, is considered to be the only one of the avian influenza, influenza A and other serious outbreaks of the drug has significant efficacy. 2005 worldwide avian influenza outbreaks are serious, 2009 worldwide influenza A outbreaks are serious, orders from countries around the world snowballed, the world's first time in the world, the world's first time in the world. Orders for Tamiflu from all over the world snowballed to Roche's headquarters, and Tamiflu was in short supply. Sources say that the global sales of Tamiflu in 2001 was only 76 million U.S. dollars, while the outbreak of avian influenza in 2005, this figure has soared to 700 million U.S. dollars, Roche expects the sales of the drug in 2005 more than 1 billion U.S. dollars. Roche's unwillingness to relinquish its patents for a significant period of time and its failure to engage in effective campaigns to expand Tamiflu production capacity drew international condemnation that "Roche is putting its own interests ahead of human health." In response to the influenza pandemic, Roche later stated that it would "accept applications from any company capable of producing the drug" and expanded its production capacity worldwide. Although in some countries, some patients after taking Tamiflu adverse reactions and outbreaks of murder, but in recent years, avian flu, influenza A ravaged the serious situation, Tamiflu contribution to human health is still invaluable.